Efficacy and safety of ramucirumab plus carboplatin and paclitaxel in untreated metastatic thymic carcinoma: RELEVENT phase II trial (NCT03921671)

被引：9

作者：

Proto, C. ^{[1
]}

Ganzinelli, M. ^{[1
]}

Manglaviti, S. ^{[1
]}

Imbimbo, M. ^{[1
,2
]}

Galli, G. ^{[1
,16
]}

Marabese, M. ^{[3
]}

Zollo, F. ^{[4
]}

Alvisi, M. F. ^{[4
]}

Perrino, M. ^{[5
]}

Cordua, N. ^{[5
]}

Borea, F. ^{[6
]}

de Vincenzo, F. ^{[5
]}

Chella, A. ^{[7
]}

Cappelli, S. ^{[7
]}

Pardini, E. ^{[7
]}

Ballatore, Z. ^{[8
]}

Lucarelli, A. ^{[8
]}

Ambrosini, E. ^{[9
]}

Giuliano, M. ^{[10
,11
]}

Pietroluongo, E. ^{[10
]}

Mulargiu, C. ^{[12
]}

Fabbri, A. ^{[13
]}

Prelaj, A. ^{[1
]}

Occhipinti, M. ^{[1
]}

Brambilla, M. ^{[1
]}

Mazzeo, L. ^{[1
]}

Beninato, T. ^{[1
]}

Vigorito, R. ^{[14
]}

Ruggirello, M. ^{[14
]}

Greco, F. G. ^{[14
]}

Calareso, G. ^{[14
]}

Miliziano, D. ^{[1
]}

Rulli, E. ^{[4
]}

De Simone, I. ^{[4
]}

Torri, V. ^{[4
]}

de Braud, F. G. M. ^{[1
,15
]}

Pasello, G. ^{[12
,16
]}

De Placido, P.

Berardi, R. ^{[9
]}

Petrini, I. ^{[17
]}

Zucali, P. ^{[5
,6
]}

Garassino, M. C. ^{[1
,18
]}

Lo Russo, G. ^{[1
]}

机构：

[1] Fdn IRCCS Ist Nazl Tumori, Med Oncol Dept, Milan, Italy

[2] EOC, Oncol Inst Southern Switzerland, Bellinzona, Switzerland

[3] Ist Ric Farmacolog Mario Negri IRCCS, Lab Mol Pharmacol, Milan, Italy

[4] Ist Ric Farmacolog Mario Negri IRCCS, Methodol Clin Res Lab, Milan, Italy

[5] IRCCS Humanitas Res Hosp, Dept Oncol, Milan, Italy

[6] Humanitas Univ, Dept Biomed Sci, Milan, Italy

[7] Azienda Osped Univ Pisana, Pneumol Unit, Pisa, Italy

[8] Azienda Osped Univ Marche, Dept Med Oncol, Ancona, Italy

[9] Univ Politecn Marche, Dept Clin & Mol Sci, Ancona, Italy

[10] Univ Federico II, Dept Clin Med & Surg, Naples, Italy

[11] Rare Tumors Coordinating Ctr Campania Reg CRCTR, Naples, Italy

[12] Ist Oncol Venetod IRCCS, Med Oncol 2, Padua, Italy

[13] Fdn IRCCS Ist Nazl Tumori, Dept Pathol, Milan, Italy

[14] Fdn IRCCS Ist Nazl Tumori, Dept Intervent Radiol, Milan, Italy

[15] Univ Milan, Dept Oncol & Hemato Oncol, Milan, Italy

[16] Univ Padua, Dept Surg Oncol & Gastroenterol, Padua, Italy

[17] Univ Pisa, Dept Translat Res & New Technol Med & Surg, Med Oncol, Pisa, Italy

[18] Univ Chicago, Dept Med, Thorac Oncol Program, Sect Hematol Oncol, Chicago, IL USA

来源：

ANNALS OF ONCOLOGY | 2024年 / 35卷 / 09期

关键词：

thymic carcinoma; ramucirumab; antiangiogenics; fi rst line; chemotherapy; EPITHELIAL TUMORS; OPEN-LABEL; CHEMOTHERAPY; MALIGNANCIES; MULTICENTER; SUNITINIB; CISPLATIN; THERAPY; THYMOMA;

D O I：

10.1016/j.annonc.2024.06.002

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

Background: Thymic carcinoma (TC) is a rare tumor with aggressive behavior. Chemotherapy with carboplatin plus paclitaxel represents the treatment of choice for advanced disease. Antiangiogenic drugs, including ramucirumab, have shown activity in previously treated patients. The RELEVENT trial was designed to evaluate the activity and safety of ramucirumab plus chemotherapy as first-line treatment in advanced TC. Patients and methods: This phase II trial was conducted within the Italian TYME network. Eligible patients had treatment-na & iuml;ve advanced TC. They received ramucirumab, carboplatin and paclitaxel for six cycles, followed by ramucirumab maintenance until disease progression or intolerable toxicity. Primary endpoint was objective response rate (ORR) according to RECIST v1.1 as assessed by the investigator. Secondary endpoints were progression-free survival (PFS), overall survival (OS) and safety. Centralized radiologic review was carried out. Results: From November 2018 to June 2023, 52 patients were screened and 35 were enrolled. Median age was 60.8 performance status was 0 in 68.5% and 1 in 31.4% of patients. At the present analysis carried out some months after the interim analysis (earlier than expected) on 35 patients, ORR was 80.0% [95% confidence interval (CI) 63.1% to 91.6%]. At the centralized radiological review of 33/35 assessable patients, ORR was 57.6% (95% CI 39.2% to 74.5%). After a median follow-up of 31.6 months, median PFS was 18.1 months (95% CI 10.8-52.3 months) and median OS was 43.8 months (95% CI 31.9 months-not reached). Thirty-two out of 35 patients (91.4%) experienced at least one treatment-related adverse event (AE), of which 48.6% were AE >= grade 3. Conclusions: In previously untreated advanced TC, the addition of ramucirumab to carboplatin and paclitaxel showed the highest activity compared to historical controls, with a manageable safety profile. Despite the small number of patients, given the rarity of the disease, the trial results support the consideration of this combination as first-line treatment in TC.

引用

页码：817 / 826

页数：10

共 50 条

[31] Protocol of a phase II study investigating the efficacy and safety of trifluridine/tipiracil plus ramucirumab as a third-line or later treatment for advanced gastric cancer [J].

Nakanishi, Koki ;

Tanaka, Chie ;

Kanda, Mitsuro ;

Miyata, Kazushi ;

Machida, Nozomu ;

Sakai, Mitsuru ;

Kobayashi, Daisuke ;

Teramoto, Hitoshi ;

Ishiyama, Akiharu ;

Sato, Bin ;

Oshima, Takashi ;

Kajikawa, Masaki ;

Matsushita, Hidenobu ;

Ishigure, Kiyoshi ;

Yamashita, Katsuya ;

Fujitake, Shinichi ;

Sueoka, Satoshi ;

Asada, Takahiro ;

Shimizu, Dai ;

Sugita, Shizuki ;

Kuwatsuka, Yachiyo ;

Maeda, Osamu ;

Furune, Satoshi ;

Murotani, Kenta ;

Ando, Yuichi ;

Ebata, Tomoki ;

Kodera, Yasuhiro .

NAGOYA JOURNAL OF MEDICAL SCIENCE, 2024, 86 (01) :43-51

[32] Pembrolizumab Plus Carboplatin and Paclitaxel as First-Line Therapy for Recurrent/Metastatic Head and Neck Squamous Cell Carcinoma (KEYNOTE-B10): A Single-Arm Phase IV Trial [J].

Dzienis, Marcin ;

Cundom, Juan ;

Fuentes, Christian Sebastian ;

Spreafico, Anna ;

Nordlinger, Melanie ;

Pastor, Andrea Viviana ;

Alesi, Erin ;

Neki, Anterpreet ;

Fung, Andrea S. ;

Lima, Iane Pinto Figueiredo ;

Oppelt, Peter ;

da Cunha Junior, Geraldo Felicio ;

Burtness, Barbara ;

Franke, Fabio Andre ;

Tseng, Jennifer E. ;

Joshi, Abhishek ;

Mccarthy, Joy ;

Swaby, Ramona ;

Sidi, Yulia ;

Gumuscu, Burak ;

Naicker, Niroshini ;

de Castro Jr, Gilberto .

JOURNAL OF CLINICAL ONCOLOGY, 2024, 42 (25) :2989-2999

[33] Phase II trial of dose-dense doxorubicin plus gemcitabine followed by paclitaxel plus carboplatin in patients with advanced urothelial carcinoma and impaired renal function [J].

Galsky, Matthew D. ;

Iasonos, Alexia ;

Mironov, Svetlana ;

Scattergood, Joseph ;

Boyle, Mary G. ;

Bajorin, Dean F. .

CANCER, 2007, 109 (03) :549-555

[34] Phase II Trial of Bevacizumab Plus Weekly Paclitaxel, Carboplatin, and Metronomic Cyclophosphamide With or Without Trastuzumab and Endocrine Therapy as Preoperative Treatment of Inflammatory Breast Cancer [J].

Palazzo, Antonella ;

Dellapasqua, Silvia ;

Munzone, Elisabetta ;

Bagnardi, Vincenzo ;

Mazza, Manuelita ;

Cancello, Giuseppe ;

Ghisini, Raffaella ;

Iorfida, Monica ;

Montagna, Emilia ;

Goldhirsch, Aaron ;

Colleoni, Marco .

CLINICAL BREAST CANCER, 2018, 18 (04) :328-335

[35] Capecitabine plus paclitaxel versus epirubicin plus paclitaxel as first-line treatment for metastatic breast cancer: efficacy and safety results of a randomized, phase III trial by the AGO Breast Cancer Study Group [J].

Lueck, Hans-Joachim ;

Du Bois, Andreas ;

Loibl, Sibylle ;

Schrader, Iris ;

Huober, Jens ;

Heilmann, Volker ;

Beckmann, Matthias ;

Staehler, Ann ;

Jackisch, Christian ;

Hubalek, Michael ;

Richter, Barbara ;

Stickeler, Elmar ;

Eidtmann, Holger ;

Thomssen, Christoph ;

Untch, Michael ;

Wollschlaeger, Kerstin ;

Schuster, Tibor ;

von Minckwitz, Gunter .

BREAST CANCER RESEARCH AND TREATMENT, 2013, 139 (03) :779-787

[36] A Phase I/II Study of Necitumumab Plus Pembrolizumab, Nab-Paclitaxel, and Carboplatin for Previously Untreated Advanced Squamous Non-Small Cell Lung Cancer Study: (NEJ048A/NEXUS) [J].

Miyanaga, Akihiko ;

Asahina, Hajime ;

Watanabe, Satoshi ;

Shukuya, Takehito ;

Tsubata, Yukari ;

Hosomi, Yukio ;

Sugawara, Shunichi ;

Maemondo, Makoto ;

Okano, Tetsuya ;

Morita, Satoshi ;

Matsuyama, Kotone ;

Kobayashi, Kunihiko ;

Seike, Masahiro .

CLINICAL LUNG CANCER, 2023, 24 (04) :371-375

[37] Phase II Trial of Pemetrexed Plus Gemcitabine in Patients With Locally Advanced and Metastatic Nonclear Cell Renal Cell Carcinoma [J].

Richey, Stephen L. ;

Tamboli, Pheroze ;

Ng, Chaan S. ;

Lin, E. ;

Lim, Zita D. ;

Araujo, John C. ;

Jonasch, Eric ;

Sharma, Padmanee ;

Pagliaro, Lance C. ;

Tannir, Nizar M. .

AMERICAN JOURNAL OF CLINICAL ONCOLOGY-CANCER CLINICAL TRIALS, 2013, 36 (05) :450-454

[38] Phase II trial of a paclitaxel-carboplatin combination in recurrent squamous cell carcinoma of the head and neck [J].

Pivot, X ;

Cals, L ;

Cupissol, D ;

Guardiola, E ;

Tchiknavorian, X ;

Guerrier, P ;

Merad, L ;

Wendling, JL ;

Barnouin, L ;

Savary, J ;

Thyss, A ;

Schneider, M .

ONCOLOGY, 2001, 60 (01) :66-71

[39] Randomized, Double-Blind Phase II Trial With Prospective Classification by ATM Protein Level to Evaluate the Efficacy and Tolerability of Olaparib Plus Paclitaxel in Patients With Recurrent or Metastatic Gastric Cancer [J].

Bang, Yung-Jue ;

Im, Seock-Ah ;

Lee, Keun-Wook ;

Cho, Jae Yong ;

Song, Eun-Kee ;

Lee, Kyung Hee ;

Kim, Yeul Hong ;

Park, Joon Oh ;

Chun, Hoo Geun ;

Zang, Dae Young ;

Fielding, Anitra ;

Rowbottom, Jacqui ;

Hodgson, Darren ;

O'Connor, Mark J. ;

Yin, Xiaolu ;

Kim, Woo Ho .

JOURNAL OF CLINICAL ONCOLOGY, 2015, 33 (33) :3858-+

[40] Paclitaxel Plus Carboplatin Versus Paclitaxel Plus Cisplatin in Metastatic or Recurrent Cervical Cancer: The Open-Label Randomized Phase III Trial JCOG0505 [J].

Kitagawa, Ryo ;

Katsumata, Noriyuki ;

Shibata, Taro ;

Kamura, Toshiharu ;

Kasamatsu, Takahiro ;

Nakanishi, Toru ;

Nishimura, Sadako ;

Ushijima, Kimio ;

Takano, Masashi ;

Satoh, Toyomi ;

Yoshikawa, Hiroyuki .

JOURNAL OF CLINICAL ONCOLOGY, 2015, 33 (19) :2129-U151

← 1 2 3 4 5 →